



Express Mail Label No. \_\_\_\_\_

Dated: \_\_\_\_\_

Docket No.: 00630/100M091-US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Peter Bodine

Application No.: 10/666,851

Confirmation No.: 6790

Filed: September 19, 2003

Art Unit: N/A

For: PHARMACEUTICAL COMPOSITIONS  
AND METHODS OF USING SECRETED  
FRIZZLED RELATED PROTEIN

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)). Thus, it is believed no fee is due.

A copy of each document on the PTO/SB/08 is attached.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: February 12, 2004

Respectfully submitted,

By   
Heather Morehouse Ettinger, Ph.D.

Registration No.: 51,658  
DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700  
(212) 753-6237 (Fax)  
Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/666,851-Conf. #6790
				Filing Date	September 19, 2003
				First Named Inventor	Peter Bodine
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	00630/100M091-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO-98/16641-A1	04-23-1998	The Government of the United States of America (The Secretary, Department of Health and Human Services)		
	BB	WO-98/54325-A1	12-03-1998	The Government of the United States of America (The Secretary, Department of Health and Human Services)		
	BC	WO-95/02687-A1	01-26-1995	Mayo Foundation Education and Research		
	BD	WO-02/055547-A2	07-18-2002	The Government of the United States of America (The Secretary, Department of Health and Human Services), et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Keming Lin, et al., "The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling", Proc. Natl. Acad. Sci., Vol. 94, October 1997, pp. 11196-11200.		
	CB	Thomas Mayr, et al., "Fritz: a secreted frizzled-related protein that inhibits Wnt activity", Mechanisms of Development 63(1997), pp. 109-125.		
	CC	Bang Hoang, et al., "Primary Structure and Tissue Distribution of FRZB, a Novel Protein Related to Drosophila Frizzled, Suggest a Role in Skeletal Morphogenesis", The Journal of Biological Chemistry, Vol. 271, No. 42, October 18, 1996, pp. 26131-26137.		
	CD	Paul W. Finch, et al., "Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action", Proc. Natl. Acad. Sci., Vol. 94, June 1997, pp. 6770-6775.		
	CE	Randall T. Moon, et al., "Structurally Related Receptors and Antagonists Compete for Secreted Wnt Ligands", Cell, Vol. 88, March 1997, pp. 725-728.		
	CF	Amir Rattner, et al., "A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors", Proc. Natl. Acad. Sci., Vol. 94, April 1997, pp. 2859-2863.		
	CG	Hovsep S. Melkonyan, et al., "SARPs: A family of secreted apoptosis-related proteins", Proc.		
Examiner Signature		Date Considered		



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/666,851-Conf. #6790
				Filing Date	September 19, 2003
				First Named Inventor	Peter Bodine
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	00630/100M091-US1

		Natl. Acad. Sci., Vol. 94, December 1997, pp. 13636-13641.	
	CH	Stavros C. Manolagas, "Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis <sup>1</sup> ", Endocrine Reviews 2000, 21(2), pp. 115-137.	
	CI	Bodine, et al., J. Bone Miner. Res. 1996, 11:806-819.	
	CJ	Steven L. Teitelbaum, "Bone Resorption by Osteoclasts", Science, Vol. 289, September 2000, pp. 1504-1508.	
	CK	David Goltzman, "Discoveries, Drugs and Skeletal Disorders", Nature Reviews, Vol. 1, October 2002, pp. 784-796.	
	CL	Robert S. Weinstein and Manolagas, "Apoptosis and Osteoporosis" The American Journal of Medicine, February 2000, Vol. 108, pp. 153-164.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--